

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 October 2000 (05.10.2000)

PCT

(10) International Publication Number  
WO 00/57865 A3(51) International Patent Classification: A61K 31/665,  
A61P 43/00, 35/00, 35/02, 3/10, C07F 9/6574(74) Agent: REINHOLD COHN AND PARTNERS; P.O.  
Box 4060, 61040 Tel Aviv (IL).

(21) International Application Number: PCT/IL00/00185

(22) International Filing Date: 24 March 2000 (24.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 129178 25 March 1999 (25.03.1999) IL


(71) Applicant (for all designated States except US): YEDA  
RESEARCH AND DEVELOPMENT CO. LTD.  
[IL/IL]; at the Weizmann Institute of Science, P.O. Box  
95, 76100 Rehovot (IL).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(72) Inventor; and  
(75) Inventor/Applicant (for US only): SHINITZKY, Meir  
[IL/IL]; 20 Derech Haganim Street, 46910 Kfar Shmaryahu  
(IL).(88) Date of publication of the international search report:  
28 June 2001

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC GLYCEROPHOSPHATES AND ANALOGS  
THEREOF FOR PROMOTING NEURAL CELL DIFFERENTIATION

(57) Abstract: Cyclic glycerophosphates and analogs thereof (CGs) are shown to exert neural promoting activities in target cells. Such activities include promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminergic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve rescue. These activities of the CGs render them useful for treatment of various disorders including but not limited to mental disorders such as, for example, schizophrenia, dementia or disorders resulting in learning disabilities. In addition, these CGs may be used for the treatment of neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, conditions resulting from exposure to harmful environmental factors or resulting from a mechanical injury. The CGs may also be used to treat an individual suffering from a primary neurodegenerative condition in order to prevent or reduce the appearance of secondary degeneration in additional nerves ("nerve rescue").